Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Jun;31(6):643–647. doi: 10.1111/j.1365-2125.1991.tb05586.x

A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine.

Q Y Yue 1, J O Svensson 1, F Sjöqvist 1, J Säwe 1
PMCID: PMC1368573  PMID: 1867958

Abstract

1. The kinetics of codeine and metabolites were studied in eight unrelated healthy Chinese subjects following a single oral dose of 50 mg codeine phosphate. The data were compared with those from eight Caucasian subjects who were matched with the Chinese group according to their metabolic ratio (MR) of debrisoquine. 2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h). Thus plasma clearance was significantly lower (P less than 0.02) and the plasma half-life was longer (P less than 0.05) in the Chinese. 3. Partial clearance by glucuronidation was significantly lower (0.79 +/- 0.14 s.d. vs 1.42 +/- 0.48 s.d. 1 h-1 kg-1) in Chinese than in Caucasians. 4. The total urinary recovery of drug-related material in 48 h urine was similar in Chinese (82.2%) and Caucasians (84.4%). The recovery of unchanged codeine was significantly higher in Chinese (5.7%) than in Caucasians (3.3%). 5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese. The corresponding ratios in Caucasians were 1:15, 50:1 and 6:1. 6. There was no significant difference between Chinese and Caucasians in the renal clearances of codeine and its primary metabolites. 7. Large interethnic differences in the kinetics of codeine have been shown. The Chinese are less able to metabolise codeine mainly because of a lower efficiency in glucuronidation.

Full text

PDF
643

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADLER T. K., FUJIMOTO J. M., WAY E. L., BAKER E. M. The metabolic fate of codeine in man. J Pharmacol Exp Ther. 1955 Jul;114(3):251–262. [PubMed] [Google Scholar]
  2. Chen Z. R., Somogyi A. A., Bochner F. Polymorphic O-demethylation of codeine. Lancet. 1988 Oct 15;2(8616):914–915. doi: 10.1016/s0140-6736(88)92529-9. [DOI] [PubMed] [Google Scholar]
  3. Dayer P., Desmeules J., Leemann T., Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun. 1988 Apr 15;152(1):411–416. doi: 10.1016/s0006-291x(88)80729-0. [DOI] [PubMed] [Google Scholar]
  4. Ghoneim M. M., Korttila K., Chiang C. K., Jacobs L., Schoenwald R. D., Mewaldt S. P., Kayaba K. O. Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther. 1981 Jun;29(6):749–756. doi: 10.1038/clpt.1981.106. [DOI] [PubMed] [Google Scholar]
  5. Guay D. R., Awni W. M., Findlay J. W., Halstenson C. E., Abraham P. A., Opsahl J. A., Jones E. C., Matzke G. R. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther. 1988 Jan;43(1):63–71. doi: 10.1038/clpt.1988.12. [DOI] [PubMed] [Google Scholar]
  6. Guay D. R., Awni W. M., Halstenson C. E., Findlay J. W., Opsahl J. A., Abraham P. A., Jones E. C., Matzke G. R. Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. J Clin Pharmacol. 1987 Dec;27(12):983–987. doi: 10.1002/j.1552-4604.1987.tb05601.x. [DOI] [PubMed] [Google Scholar]
  7. Horai Y., Nakano M., Ishizaki T., Ishikawa K., Zhou H. H., Zhou B. I., Liao C. L., Zhang L. M. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther. 1989 Aug;46(2):198–207. doi: 10.1038/clpt.1989.126. [DOI] [PubMed] [Google Scholar]
  8. Kalow W., Otton S. V., Kadar D., Endrenyi L., Inaba T. Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. Can J Physiol Pharmacol. 1980 Sep;58(9):1142–1144. doi: 10.1139/y80-173. [DOI] [PubMed] [Google Scholar]
  9. Kalow W. Pharmacoanthropology: drug metabolism. Fed Proc. 1984 May 15;43(8):2326–2331. [PubMed] [Google Scholar]
  10. Kumana C. R., Lauder I. J., Chan M., Ko W., Lin H. J. Differences in diazepam pharmacokinetics in Chinese and white Caucasians--relation to body lipid stores. Eur J Clin Pharmacol. 1987;32(2):211–215. doi: 10.1007/BF00542199. [DOI] [PubMed] [Google Scholar]
  11. LASAGNA L., DE KORNFELD T. J. Analgesic potency of normorphine in patients with postoperative pain. J Pharmacol Exp Ther. 1958 Nov;124(3):260–263. [PubMed] [Google Scholar]
  12. Lennard M. S., Silas J. H., Smith A. J., Tucker G. T. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr. 1977 Mar 11;133(1):161–166. doi: 10.1016/s0021-9673(00)89216-x. [DOI] [PubMed] [Google Scholar]
  13. Lou Y. C., Ying L., Bertilsson L., Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. 1987 Oct 10;2(8563):852–853. doi: 10.1016/s0140-6736(87)91034-8. [DOI] [PubMed] [Google Scholar]
  14. MILLER J. W., ANDERSON H. H. The effect of N-demethylation on certain pharmacologic actions of morphine, codeine, and meperidine in the mouse. J Pharmacol Exp Ther. 1954 Oct;112(2):191–196. [PubMed] [Google Scholar]
  15. Mortimer O., Persson K., Ladona M. G., Spalding D., Zanger U. M., Meyer U. A., Rane A. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther. 1990 Jan;47(1):27–35. doi: 10.1038/clpt.1990.4. [DOI] [PubMed] [Google Scholar]
  16. Mucklow J. C., Fraser H. S., Bulpitt C. J., Kahn C., Mould G., Dollery C. T. Environmental factors affecting paracetamol metabolism in London factory and office workers. Br J Clin Pharmacol. 1980 Jul;10(1):67–74. doi: 10.1111/j.1365-2125.1980.tb00503.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
  18. Osborne R., Joel S., Trew D., Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet. 1988 Apr 9;1(8589):828–828. doi: 10.1016/s0140-6736(88)91691-1. [DOI] [PubMed] [Google Scholar]
  19. Quiding H., Anderson P., Bondesson U., Boréus L. O., Hynning P. A. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol. 1986;30(6):673–677. doi: 10.1007/BF00608214. [DOI] [PubMed] [Google Scholar]
  20. Rogers J. F., Findlay J. W., Hull J. H., Butz R. F., Jones E. C., Bustrack J. A., Welch R. M. Codeine disposition in smokers and nonsmokers. Clin Pharmacol Ther. 1982 Aug;32(2):218–227. doi: 10.1038/clpt.1982.151. [DOI] [PubMed] [Google Scholar]
  21. Spector R., Choudhury A. K., Chiang C. K., Goldberg M. J., Ghoneim M. M. Diphenhydramine in Orientals and Caucasians. Clin Pharmacol Ther. 1980 Aug;28(2):229–234. doi: 10.1038/clpt.1980.155. [DOI] [PubMed] [Google Scholar]
  22. Yue Q. Y., Bertilsson L., Dahl-Puustinen M. L., Säwe J., Sjöqvist F., Johansson I., Ingelman-Sundberg M. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet. 1989 Oct 7;2(8667):870–870. doi: 10.1016/s0140-6736(89)93041-9. [DOI] [PubMed] [Google Scholar]
  23. Yue Q. Y., Hasselström J., Svensson J. O., Säwe J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1991 Jun;31(6):635–642. doi: 10.1111/j.1365-2125.1991.tb05585.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Yue Q. Y., Svensson J. O., Alm C., Sjöqvist F., Säwe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol. 1989 Dec;28(6):639–645. doi: 10.1111/j.1365-2125.1989.tb03556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yue Q. Y., Svensson J. O., Alm C., Sjöqvist F., Säwe J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol. 1989 Dec;28(6):629–637. doi: 10.1111/j.1365-2125.1989.tb03555.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yue Q., von Bahr C., Odar-Cederlöf I., Säwe J. Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol Toxicol. 1990 Mar;66(3):221–226. doi: 10.1111/j.1600-0773.1990.tb00737.x. [DOI] [PubMed] [Google Scholar]
  27. Zhang Y. A., Reviriego J., Lou Y. Q., Sjöqvist F., Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther. 1990 Nov;48(5):496–502. doi: 10.1038/clpt.1990.185. [DOI] [PubMed] [Google Scholar]
  28. Zhou H. H., Koshakji R. P., Silberstein D. J., Wilkinson G. R., Wood A. J. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med. 1989 Mar 2;320(9):565–570. doi: 10.1056/NEJM198903023200905. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES